Biohaven Launches Phase 2 Trial of TRPM3 Antagonist BHV-2100 for Acute Migraine Treatment
核心洞察
Biohaven (搜索) has initiated a Phase 2 clinical trial to evaluate BHV-2100, a novel, orally administered TRPM3 (搜索) antagonist, for the acute treatment of migraine (搜索).
The trial is a randomized, double-blind, placebo-controlled study assessing the efficacy and safety of two BHV-2100 doses (75 mg and 150 mg) in approximately 575 patients.
BHV-2100 demonstrated a favorable safety profile in Phase 1 trials and targets the TRPM3 (搜索) ion channel, which has been implicated in migraine (搜索) pathophysiology.
Biohaven (搜索) Ltd. has commenced a pivotal Phase 2 clinical trial to investigate BHV-2100, a potential first-in-class, orally administered Transient Receptor Potential Melastatin-3 (TRPM3 (搜索)) antagonist, for the acute treatment of migraine (搜索). The trial aims to evaluate the efficacy and safety of BHV-2100 in alleviating migraine symptoms, addressing a significant unmet need in the treatment of this debilitating condition that affects approximately 40 million people in the US and 1 billion worldwide.
The randomized, double-blind, placebo-controlled trial will enroll approximately 575 patients across 60 sites in the United States. Participants experiencing acute migraine (搜索) will be administered either 75 mg or 150 mg doses of BHV-2100 or a placebo. The co-primary endpoints for the study are pain freedom and freedom from the most bothersome symptom (MBS) at 2 hours post-dose. Secondary endpoints include pain relief at 2 hours, return to normal function, sustained pain relief, freedom from photophobia, and the use of rescue medication.
Novel Mechanism Targeting TRPM3
BHV-2100 is designed as a potent, selective, and non-opioid investigational treatment. The TRPM3 (搜索) ion channel has been identified as a key player in the pathophysiology of migraine (搜索). Richard B. Lipton, M.D., Director of the Montefiore Headache Center, noted, "The TRPM3 ion channel has been implicated in the pathophysiology of migraine, and this trial is the first to assess efficacy and tolerability of a novel agent targeting this mechanism in migraine."
Safety and Pharmacokinetics
Previous Phase 1 trials have indicated that BHV-2100 has a favorable safety and tolerability profile. The drug demonstrated rapid absorption and sustained concentrations, with maximal drug concentrations achieved approximately 1.5 to 2 hours post-dose and a half-life of 8-12 hours. Beth Emerson, M.D., Executive Medical Director at Biohaven (搜索), emphasized the company's commitment to advancing novel therapeutic options, particularly for the estimated one-third of migraine (搜索) patients who do not respond adequately to existing treatments.
Trial Design and Endpoints
The Phase 2 trial (NCT06603623) will also monitor plasma concentrations of BHV-2100, adverse events, and clinically significant laboratory abnormalities. Furthermore, investigators will assess the percentage of participants with freedom from nausea and the percentage experiencing pain relapse between 2 and 48 hours post-dose.
Biohaven's Commitment to Migraine Treatment
Biohaven (搜索) has a strong track record in developing innovative medications for migraine (搜索). Beth Morris, Vice President of Biohaven Clinical Operations, stated, "Biohaven has deep expertise in running clinical trials in migraine and this study will assess an important new potential therapy for patients... if this study is positive, we will be one step closer to delivering another novel treatment option to better meet the needs of people with migraine."